| Literature DB >> 34771095 |
Raja Mohamed Beema Shafreen1, Selvaraj Alagu Lakshmi2, Shunmugiah Karutha Pandian2, Young-Mo Kim3, Joseph Deutsch4, Elena Katrich4, Shela Gorinstein4.
Abstract
Previous reports have shown that consumption of wine has several health benefits; however, there are different types of wine. In the present study, red wines were investigated for their compositions of active ingredients. The interaction of each component in terms of its binding mode with different serum proteins was unraveled, and the components were implicated as drug candidates in clinical settings. Overall, the study indicates that red wines have a composition of flavonoids, non-flavonoids, and phenolic acids that can interact with the key regions of proteins to enhance their biological activity. Among them, rutin, resveratrol, and tannic acid have shown good binding affinity and possess beneficial properties that can enhance their role in clinical applications.Entities:
Keywords: albumin; antioxidant activities; beverages; binding properties; fibrinogen; health properties; resveratrol; rutin; tannic acid
Mesh:
Substances:
Year: 2021 PMID: 34771095 PMCID: PMC8587719 DOI: 10.3390/molecules26216686
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Bioactive substances and antioxidant activities of red wines x liter.
| Indices | CSCarmel1 | CSCarmel2 | CSYarden1 | CSYarden2 |
|---|---|---|---|---|
| Polyph, mgGAE | 2190.83 ± 9.43 a | 2230.73 ± 8.72 a | 1560.33 ± 6.32 b | 1610.42 ± 6.21 b |
| Flavan, mgCE | 241.84 ± 3.62 b | 253.94 ± 2.92 ab | 272.51 ± 4.33 a | 283.63 ± 3.73 a |
| Flavon, mgCE | 408.63 ± 3.63 a | 418.63 ± 5.11 a | 292.42 ± 2.54 b | 302.62 ± 5.24 ab |
| Tannins, mgCE | 152.54 ± 1.82 a | 156.24 ± 1.42 a | 51.33 ± 0.92 b | 52.43 ± 0.73 b |
| Anthoc, mgCGE | 137.53 ± 2.24 a | 140.23 ± 2.93 a | 97.91 ± 1.83 b | 101.22 ± 2.93 b |
| ABTS, mMTE | 19.84 ± 0.34 a | 20.45 ± 1.12 a | 13.94 ± 1.11 b | 14.85 ± 1.23 b |
| FRAP, mMTE | 5.84 ± 0.54 a | 6.18 ± 0.61 a | 4.12 ± 0.34 b | 4.46 ± 0.25 ab |
| CUPRAC, mMTE | 27.11 ± 1.14 a | 28.33 ± 1.65 a | 19.64 ± 1.65 b | 20.47 ± 1.76 b |
| DPPH, mMTE | 9.65 ± 0.87 a | 10.52 ± 1.12 a | 7.14 ± 0.65 b | 7.36 ± 0.73 b |
| Rutin, mg | 8.63 ± 0.54 a | 9.25 ± 0.87 a | 6.81 ± 0.56 b | 6.53 ± 0.55 b |
| Resveratro, mg | 2.15 ± 0.18 ab | 2.98 ± 0.12 a | 1.71 ± 0.17 b | 1.91 ± 0.17 ab |
| Quercetin, mg | 7.32 ± 0.41 ab | 8.24 ± 0.61 a | 5.74 ± 0.43 c | 6.49 ± 0.43 b |
| Caffeic acid, mg | 10.15 ± 0.97 a | 11.24 ± 1.12 a | 8.64 ± 0.76 b | 9.45 ± 0.75 ab |
| Catechin, mg | 40.21 ± 0.37 a | 42.17 ± 0.46 a | 31.18 ± 0.23 b | 34.15 ± 0.22 ab |
| Epicatechin, mg | 26.14 ± 2.33 a | 28.65 ± 2.43 a | 21.94 ± 2.09 b | 23.18 ± 1.89 ab |
Values are means ± SD of five measurements; n = 5 samples per vintage, each subsampled and analyzed five times. Means within rows with the different superscripts are statistically different (p < 0.05; Student’s t-test). Abbreviations: 1, 1-diphenyl-2-picrylhydrazyl (DPPH); Polyph, polyphenols; Flavon, flavonoids; Flavan, flavanols; GAE, gallic acid equivalent; CE, catechin equivalent; TE, trolox equivalent; Anthoc, anthocyanins; CGE, cyanidin-3-glucoside equivalent; ABTS, 2, 2-Azino-bis (3-ethyl-benzothiazoline-6-sulfonic acid) diammonium salt; FRAP, Ferric-reducing/antioxidant power; CUPRAC, Cupric reducing antioxidant capacity; CSCarmel1, CSCarmel2, Cabernet Sauvignon Carmel Selected, vintages 2017, 2019; CSYarden1 and CSYarden2, Cabernet Sauvignon Golan Heights Winery Yarden, vintages 2017 and 2019.
Figure 1Fluorometric measurements in a three-dimensional fluorescence analysis (3D-FL) of red wine samples and standards after interaction with fibrinogen Cross-images of the results obtained from the 3D-FL of the investigated samples after interaction with fibrinogen are shown in the following order: (A) CSCarmel2; (B) CSYarden2; (C) tannic acid; (D) quercetin; (E) caffeic acid; (F) fibrinogen in solution. Abbreviations: CSCarmel2, Cabernet Sauvignon Carmel Selected, vintage 2019; CSYarden2, Cabernet Sauvignon Golan Heights Winery Yarden, vintage 2019. The locations of peaks a and b are shown in the figure and in Table 2 (for interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).
Figure 2Fluorometric measurements in a three-dimensional fluorescence analysis (3D-FL) of red wine samples and standards after interactions with human serum albumin (HSA). Cross-images of the results obtained from the 3D-FL of the investigated samples after their interaction with HSA are shown in the following order: (A) CSCarmel2; (B) CSYarden2; (C) tannic acid; (D) quercetin; (E) caffeic acid; (F) HSA in solution. Abbreviations: CSCarmel2, Cabernet Sauvignon Carmel Selected, vintage 2019; CSYarden2, Cabernet Sauvignon Golan Heights Winery Yarden, vintage 2019. The locations of peaks a and b are shown in the figure and in Table 2 (for interpretation of the references to color in this figure legend, the reader is referred to the web version of this article).
Spectral data of the investigated samples and some standards.
| Indices | CSCarmel 1 | CSCarmel 2 | CSYarden 1 | CSYarden 2 | Tannic Acid | Quercetin | Caffeic Acid | Ethanol | Fib/HSA |
|---|---|---|---|---|---|---|---|---|---|
| λem/ex, nm, peak | 230/341 | 230/341 | 230/340 | 230/341 | 229/343 | 228/340 | 229/340 | 228/341 | 229/342 |
| FI, A.U., peak | 468.8 ± 7.2 c | 478.4 ± 8.2 c | 484.6 ± 5.6 c | 499.6 ± 7.3 c | 657.4 ± 5.9 b | 861.0 ± 8.5 a | 836.1 ± 8.9 a | 865.5 ± 7.9 a | 883.6 ± 7.9 a |
| BP, %, peak | 46.9 ± 3.8a | 45.9 ± 6.9 a | 45.2 ± 3.4 a | 43.5 ± 7.1 a | 26.6 ± 3.9 b | 2.6 ± 0.7 d | 5.4 ± 0.7 c | 2.1 ± 0.3 d | - |
| λem/ex, nm, peak | 280/345 | 281/345 | 278/344 | 278/345 | 280/347 | 280/343 | 278/341 | 281/342 | 282/341 |
| FI, A.U., peak | 524.6 ± 9.3 c | 535.3 ± 6.9 c | 679.3 ± 5.3 bc | 702.3 ± 8.3 b | 595.9 ± 5.4 c | 706.9 ± 8.2 b | 768.7 ± 7.1 ab | 797.1 ± 7.8 ab | 811.7 ± 8.4 a |
| BP, %, peak | 35.4 ± 4.4 a | 34.1 ± 2.8 a | 16.3 ± 1.4 bc | 13.7 ± 1.2 bc | 26.6 ± 5.1 b | 12.9 ± 1.1 c | 5.3 ± 0.7 d | 1.8 ± 0.1 e | - |
| λem/ex, nm, peak | 227/356 | 228/357 | 226/354 | 226/355 | 226/358 | 229/356 | 225/358 | 228/355 | 228/353 |
| FI, A.U., peak | 406.2 ± 7.3 c | 414.5 ± 7.2 c | 411.5 ± 4.3 c | 424.9 ± 3.1c | 579.6 ± 4.7 b | 582.8 ± 5.1 b | 626.9 ± 7.4 a | 633.0 ± 9.1 a | 643.0 ± 6.3 a |
| BP, %, peak | 36.9+3.8 a | 35.5 ± 1.8 a | 36.0 ± 3.2 a | 34.0 ± 3.2 a | 9.9 ± 0.9 b | 9.4 ± 0.7 b | 2.5 ± 0.4 c | 1.6 ± 0.4 c | - |
| λem/ex, nm, peak | 278/359 | 278/359 | 279/360 | 280/360 | 280/359 | 280/356 | 279/360 | 280/356 | 280/357 |
| FI, A.U., peak | 843.0 ± 6.4 ab | 860.2 ± 7.4 ab | 771.0 ± 7.4 b | 794.8 ± 5.2 b | 818.9 ± 9.9 ab | 867.4 ± 8.8 ab | 865.5 ± 7.9 ab | 910.9 ± 8.3 a | 920.1 ± 10.3 a |
| BP, %, peak | 8.4 ± 0.7 bc | 6.5 ± 0.8 c | 16.2 ± 1.5 a | 13.6 ± 1.9 ab | 11.0 ± 1.0 b | 5.7 ± 0.4 c | 5.9 ± 0.6 c | 1.0 ± 0.9 d | - |
The values are means ± SD of five measurements with n = 5 samples per vintage, and each was subsampled and analyzed five times. Means within rows with different superscripts are statistically different (p < 0.05; Student’s t-test). Abbreviations; CSCarmel1, CSCarmel2, Cabernet Sauvignon Carmel Selected, vintages 2017 and 2019; CSYarden1 and CSYarden2, Cabernet Sauvignon Golan Heights Winery Yarden, vintages 2017 and 2019; maximum emission/excitation peak (λem/ex); fluorescence; intensity (FI); arbitral units (A.U.); fibrinogen (Fib); binding to HSA (%) and binding to Fib (%) are the percent decreases in fluorescence emissions of the fractions of the binding sites of the proteins occupied by the ligands.
Binding affinity score of wine components docked with serum proteins.
| Compound Name | PubChem ID | Binding Affinity (kcal/mol) | |||
|---|---|---|---|---|---|
| CRP | Fibrinogen | GPX3 | HSA | ||
| Epicatechin | 72276 | −7.8 | −5.1 | −6.6 | −8.9 |
| Epigallocatechin | 72277 | −8.3 | −6.3 | −6.4 | −8.6 |
| Resveratrol | 445154 | −7.4 | −6.1 | −6.8 | −9.1 |
| Rutin | 5280805 | −8.7 | −7.9 | −7.4 | −9.9 |
| Quercetin | 5280343 | −8.7 | −5.3 | −6.8 | −9.2 |
| Gallic acid | 370 | −6.3 | −5.7 | −6.2 | −6.2 |
| Tannic acid | 16129778 | −7.7 | −6.4 | −7.3 | −10.4 |
| Myricetin | 5281672 | −8.4 | −6.3 | −6.8 | −9 |
| Caffeic acid | 689043 | −6.4 | −5 | −5.7 | −7.2 |
Figure 3Interactions of ligands with the key residues of C-reactive protein (CRP). (A) The surface view represents the predicted binding pocket (green color) of the CRP; (B) the interaction of rutin with CRP; (C) the interaction of tannic acid with CRP; (D) the interaction of resveratrol with CRP.
Figure 4Molecular docking of ligands with fibrinogen. (A) Fibrinogen represented as a CPK model; expanded view of the ligands showing their interactions with the critical residues of fibrinogen; (B) rutin; (C) tannic acid; (D) resveratrol.
Figure 5In silico docking of ligands into the binding pocket of human glutathione peroxidase 3 (GPX3). (A) CPK model of GPX3 protein, in which the yellow-colored surface represents the binding pocket; the expanded views of ligands interacting with the key amino acids of GPX3 (CPK model); (B) rutin; (C) tannic acid; (D) resveratrol.
Figure 6Analysis of interactions with human serum albumin (HSA). (A) The green-colored surface represents the binding pocket of the HSA protein (CPK model). (B) Interaction of rutin with the amino acids in the binding pocket, (C) tannic acid, and (D) resveratrol.